~~<i id='09A0EA61F2'><strike id='09A0EA61F2'><tt id='09A0EA61F2'><pre id='09A0EA61F2'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：leisure time 2025-08-12 08:25:40 - browse：6

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： NIH director takes cautious approach to Biden drug pricing priority

leisure time

entertainment

leisure time

hotspot

focus

MollyFerguson/STATHello!SometakesandthoughtsonGilead’sTrodelvytroubles,ElevationOncology’ssurprising

WSS

The effects of a landmark ruling on DNA ownership are becoming clearer

AI generated plenty of interest at JPM but not a lot of trust

My yearlong odyssey to get my son’s ADHD medication covered

PBM executives asked to testify by House panel

How digital therapeutics firms are pivoting after Pear's bankruptcy

Crowdfunding for medical bills sidesteps core problem, author says

focus

hotspot

leisure time

In Memoriam: Notable people who died in 2023

Readout Newsletter: Merck, J&J, and long Covid

Malaria cases in Florida and Texas: Here’s what you need to know

Francis Collins on trust in science and how Covid communications failed

Bright Health sells Medicare Advantage business to Molina

AI generated plenty of interest at JPM but not a lot of trust

Supreme Court strikes down use of affirmative action

Why doctors need education on FDA device approval process

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

BIO to announce reorganization, senior leaders expected to depart

entertainment

Dewpoint Therapeutics lays off staff after losing partnerships

BIO to announce reorganization, senior leaders expected to depart

Primary care doctor shortage won't be solved by free med school tuition

eGenesis tests gene

FDA clears AI tool for detecting skin cancer

Independent physicians launch a new lobbying group

leisure time

hotspot

focus

focus